COURT-RULING ·Filed Aug 14, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 1/10
Horizonmonths Processed1mo ago CourtView Ruling on CourtListener
Court ruling (district)
Actionable Insight • Neutral

This is a routine procedural scheduling order with no material impact on Vir Biotechnology's business or stock. Monitor for any substantive rulings or settlement developments after the November 2026 mediation deadline.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+20d
VIR ▲ +16.50% at T+20d
NEUTRAL call ✓ call won +16.50% · α vs SPY +18.50% · entry $9.24 → $10.77
Next anchor: T+60d in 5w
Latest observation: T+32 +31.24% FF3 residual α
Entry anchored
Aug 13, 04:21 PM ET
via 1-min bar
T+1d
+1.62%
call +1.62% · α +2.10%
$9.39
settled 7w ago
T+5d
+5.84%
call +5.84% · α +7.21%
$9.78
settled 6w ago
T+20d
+16.50%
call +16.50% · α +18.50%
$10.77
settled 21d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

A joint stipulation in Smith v. Vir Biotechnology, Inc. was approved by the court, extending the mediation deadline from August 13, 2026 to November 30, 2026 to allow additional time for discovery. This is a routine procedural scheduling order with no substantive ruling on the merits of the case, and no financial exposure or business impact is stated in the document.

Court Ruling Details

Ruling Date
Aug 14, 2026
Court
United States District Court for the Northern District of California
Court Level
District
Judge
Thomas S. Hixson
Case Type
other
Ruling Type
procedural
Will It Be Appealed?
N/A (final)
Precedent Risk
LOW

Key Facts

  • The court approved a joint stipulation to extend the mediation deadline from August 13, 2026 to November 30, 2026.
  • The extension was requested to allow additional time for initial discovery, document production, and depositions.
  • No damages, injunction, or substantive ruling on the merits is present in this order.

Financial Impact

No financial exposure stated in the document.

Risk Factors

  • The underlying lawsuit could result in a material adverse outcome if not resolved at mediation, but no details on the claims or potential exposure are provided in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-43c8faf2c0-VIR
18 reports for VIR
Performance horizon
40% Hit rate 2 of 5 directional calls best @ T+60▲ +10.12%Feb 24, 2026
Filters
Rows
Reports for VIR — sortable, filterable
TypeNow
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$9.24 $9.78▲ +5.84%▲ +7.21%$11.17 (+20.89%)
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$8.89 $9.39▲ +5.62%▲ +5.67%$11.17 (+25.65%)
Jul 24, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$8.69 $8.90▲ +2.42%▲ +2.04%$11.17 (+28.54%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 2/10
$10.38 $10.02▼ −3.47%▼ −4.86%$11.17 (+7.61%)
Jun 10, 2026
16w ago
3
NEUTRAL ★ 1/10
$8.52 $9.30▲ +9.15%▲ +8.72%$11.17 (+31.10%)
Jun 10, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$8.52 $9.30▲ +9.15%▲ +8.72%$11.17 (+31.10%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.77 $8.25▼ −5.93%▼ −2.11%$11.17 (+27.37%)
May 28, 2026
18w ago
8-K
NEUTRAL ★ 2/10
$9.55 $8.77▼ −8.17%▼ −8.12%$11.17 (+16.96%)
Apr 16, 2026
24w ago
DEFA14A
NEUTRAL ★ 3/10
$10.33 $10.35▲ +0.19%▼ −0.79%$11.17 (+8.13%)
Apr 10, 2026
25w ago
8-K
NEUTRAL ★ 3/10
$9.31 $11.09▲ +19.12%▲ +15.82%$11.17 (+19.98%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access